CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24034 (2013.01); C12N 2770/24071 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); C12N 2770/24164 (2013.01)] | 30 Claims |
1. A pharmaceutical composition comprising an inactivated Zika virus preparation, wherein the inactivated Zika virus preparation comprises less than 1.0 TCID50 of residual replicating virus.
|